

Kathryn A Ellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1963299/publications.pdf>

Version: 2024-02-01

142
papers

14,096
citations

36691

53
h-index

24511

114
g-index

181
all docs

181
docs citations

181
times ranked

15898
citing authors

#	ARTICLE	IF	CITATIONS
1	Balance on the Brain: a randomised controlled trial evaluating the effect of a multimodal exercise programme on physical performance, falls, quality of life and cognition for people with mild cognitive impairmentâ€”study protocol. <i>BMJ Open</i> , 2022, 12, e054725.	0.8	4
2	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimerâ€™s Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 146-157.	1.2	3
3	Combined physical and cognitive training for older adults with and without cognitive impairment: A systematic review and network meta-analysis of randomized controlled trials. <i>Ageing Research Reviews</i> , 2021, 66, 101232.	5.0	136
4	Assessment of the DTIâ€”ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. <i>Journal of Neuroimaging</i> , 2021, 31, 569-578.	1.0	68
5	Dementia knowledge and associated factors among older Chinese adults: a cross-national comparison between Melbourne and Beijing. <i>International Psychogeriatrics</i> , 2021, 33, 1057-1067.	0.6	7
6	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	1.2	59
7	Ethnic Differences in Barriers and Enablers to Physical Activity Among Older Adults. <i>Frontiers in Public Health</i> , 2021, 9, 691851.	1.3	9
8	A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 207-226.	1.2	4
9	The Support Person's Preferences and Perspectives of Physical Activity Programs for Older Adults With Cognitive Impairment. <i>Frontiers in Public Health</i> , 2021, 9, 704561.	1.3	3
10	Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. <i>Brain Imaging and Behavior</i> , 2021, 15, 2833-2842.	1.1	1
11	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. <i>Neurobiology of Aging</i> , 2020, 89, 132-141.	1.5	28
12	Distinct effects of acute exercise and breaks in sitting on working memory and executive function in older adults: a three-arm, randomised cross-over trial to evaluate the effects of exercise with and without breaks in sitting on cognition. <i>British Journal of Sports Medicine</i> , 2020, 54, 776-781.	3.1	60
13	Combined effects of continuous exercise and intermittent active interruptions to prolonged sitting on postprandial glucose, insulin, and triglycerides in adults with obesity: a randomized crossover trial. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2020, 17, 152.	2.0	16
14	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 163-171.	1.2	13
15	Effect of lean red meat combined with a multicomponent exercise program on muscle and cognitive function in older adults: a 6-month randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 113-128.	2.2	21
16	Impact of APOE-Î¼4 carriage on the onset and rates of neocortical AÎ²-amyloid deposition. <i>Neurobiology of Aging</i> , 2020, 95, 46-55.	1.5	32
17	Alcohol Use, Mental Health, and Functional Capacity as Predictors of Workplace Disability in a Cohort With Manifest Huntingtonâ€™s Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 235-243.	0.9	2
18	Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimerâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 115.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Physical activity for older Australians with mild cognitive impairment or subjective cognitive decline – A narrative review to support guideline development. <i>Journal of Science and Medicine in Sport</i> , 2020, 23, 913-920.	0.6	20
20	Targeted physical activity for older adults with mild cognitive impairment and subjective cognitive decline. <i>Medical Journal of Australia</i> , 2019, 210, 394.	0.8	6
21	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
22	Morning exercise mitigates the impact of prolonged sitting on cerebral blood flow in older adults. <i>Journal of Applied Physiology</i> , 2019, 126, 1049-1055.	1.2	39
23	Effect of Morning Exercise With or Without Breaks in Prolonged Sitting on Blood Pressure in Older Overweight/Obese Adults. <i>Hypertension</i> , 2019, 73, 859-867.	1.3	33
24	A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer’s Disease: The AIBL Active-Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, S187-S205.	1.2	18
25	Depression and physical activity research in older age: An important gap to fill. <i>Psychology of Sport and Exercise</i> , 2019, 43, 1-3.	1.1	1
26	Physical activity for cognitive health: what advice can we give to older adults with subjective cognitive decline and mild cognitive impairment?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 61-68.	1.8	44
27	Amyloid burden and incident depressive symptoms in preclinical Alzheimer’s disease. <i>Journal of Affective Disorders</i> , 2018, 229, 269-274.	2.0	27
28	Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies – Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	1.2	96
29	Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 190-196.	0.6	19
30	Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 405-413.	1.3	20
31	Predictors of Workplace Disability in a Premanifest Huntington’s Disease Cohort. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 115-121.	0.9	9
32	Interacting effects of exercise with breaks in sitting time on cognitive and metabolic function in older adults: Rationale and design of a randomised crossover trial. <i>Mental Health and Physical Activity</i> , 2018, 15, 11-16.	0.9	10
33	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer’s disease, mild cognitive impairment, and healthy aging: A longitudinal study.. <i>Psychological Assessment</i> , 2018, 30, 1308-1316.	1.2	5
34	Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 291-300.	1.8	111
35	A “Disease Severity Index” to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. <i>Scientific Reports</i> , 2017, 7, 44368.	1.6	23
36	A randomized controlled trial of physical activity with individual goal-setting and volunteer mentors to overcome sedentary lifestyle in older adults at risk of cognitive decline: the INDIGO trial protocol. <i>BMC Geriatrics</i> , 2017, 17, 215.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 169-183.	1.2	21
38	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017, 13, 388-398.	0.4	23
39	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.4	375
40	Subjective Memory Complaints in APOE ε4 Carriers are Associated with High Amyloid-β Burden. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1115-1122.	1.2	45
41	Acute effects of breaking up prolonged sitting on fatigue and cognition: a pilot study. <i>BMJ Open</i> , 2016, 6, e009630.	0.8	115
42	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 354-361.	1.1	37
43	Why attend a memory clinic? What do patients and their families want and/or expect?. <i>Australasian Journal on Ageing</i> , 2016, 35, 220-224.	0.4	9
44	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 796-804.	0.4	135
45	Comparing the Performance of the HADS and the GDS-15 in the AIBL Study. <i>International Psychogeriatrics</i> , 2015, 27, 1577-1578.	0.6	3
46	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. <i>British Journal of Nutrition</i> , 2015, 114, 1683-1693.	1.2	5
47	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease.. <i>Neuropsychology</i> , 2015, 29, 571-581.	1.0	43
48	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 175-187.	1.2	47
49	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	1.2	317
50	Alterations in dorsal and ventral posterior cingulate connectivity in APOE ε4 carriers at risk of Alzheimer's disease. <i>BJPsych Open</i> , 2015, 1, 139-148.	0.3	5
51	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	1.2	28
52	The effects of a protein enriched diet with lean red meat combined with a multi-modal exercise program on muscle and cognitive health and function in older adults: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 339.	0.7	34
53	Semi-automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1631-1638.	1.9	9
54	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015, 10, e0139082.	1.1	22

#	ARTICLE	IF	CITATIONS
55	APOE ϵ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1239-1244.	1.5	75
56	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015, 36, S159-S166.	1.5	96
57	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and A β Accumulation in Cognitively Normal Older Adults and Adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 49-58.	0.3	40
58	Longitudinal cognitive decline in the AIBL cohort: The role of APOE ϵ 4 status. <i>Neuropsychologia</i> , 2015, 75, 411-419.	0.7	27
59	Amyloid- β 2, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. <i>JAMA Psychiatry</i> , 2015, 72, 284.	6.0	160
60	Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. <i>Age and Ageing</i> , 2015, 44, 1012-1019.	0.7	31
61	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. <i>PLoS ONE</i> , 2014, 9, e84777.	1.1	43
62	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e86498.	1.1	75
63	Age-related changes to the neural correlates of working memory which emerge after midlife. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 70.	1.7	15
64	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. <i>Frontiers in Neurology</i> , 2014, 4, 205.	1.1	176
65	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014, 204, 400-401.	1.7	29
66	Disclosing a dementia diagnosis: what do patients and family consider important?. <i>International Psychogeriatrics</i> , 2014, 26, 1263-1272.	0.6	21
67	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014, 26, 543-554.	0.6	37
68	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1266-1273.	1.5	125
69	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014, 26, 1737-1746.	0.6	9
70	Physical activity program preferences and perspectives of older adults with and without cognitive impairment. <i>Asia-Pacific Psychiatry</i> , 2014, 6, 179-190.	1.2	44
71	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.4	1,863
72	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 221-231.	3.7	182

#	ARTICLE	IF	CITATIONS
73	What is frontotemporal dementia?. <i>Maturitas</i> , 2014, 79, 216-219.	1.0	18
74	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014, 83, 1345-1352.	1.5	58
75	Response to Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. <i>Diabetes Care</i> 2013;36:2981-2987. <i>Diabetes Care</i> , 2014, 37, e151-e151.	4.3	4
76	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 661-668.	1.2	76
77	A β and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 743.	0.4	66
78	Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging. <i>Annals of Epidemiology</i> , 2014, 24, 63-71.	0.9	61
79	An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. <i>Journal of Neuroimmunology</i> , 2014, 273, 65-71.	1.1	87
80	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 53-61.	0.4	114
81	Plasma Amyloid- β Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 95-104.	1.2	41
82	Amyloid- β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 677-686.	1.2	63
83	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. <i>BMC Bioinformatics</i> , 2014, 15, S11.	1.2	67
84	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 551-561.	1.2	10
85	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. <i>BMC Psychology</i> , 2013, 1, 30.	0.9	153
86	Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. <i>Diabetes Care</i> , 2013, 36, 2981-2987.	4.3	308
87	Predicting Alzheimer disease with β -amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013, 74, 905-913.	2.8	194
88	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 171-182.	1.2	46
89	A β amyloid, cognition, and <i>APOE</i> genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013, 9, 538-545.	0.4	51
90	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20

#	ARTICLE	IF	CITATIONS
91	O4-07-01: Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL)., 2013, 9, P695-P695.		0
92	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 357-367.	4.9	1,738
93	BDNF Val66Met, $A\beta$ amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2457-2464.	1.5	109
94	Cross-sectional and Longitudinal Analysis of the Relationship Between $A\beta$ Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 903.	4.5	170
95	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 34, 861-871.	1.2	42
96	Lack of reliable evidence for a distinctive β -related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. <i>Brain</i> , 2013, 136, 2201-2216.	3.7	28
97	Rapid cognitive decline in Alzheimer's disease: a literature review. <i>International Review of Psychiatry</i> , 2013, 25, 650-658.	1.4	38
98	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 320-330.	0.3	90
99	Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: An update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. <i>International Review of Psychiatry</i> , 2013, 25, 699-710.	1.4	15
100	The association of $A\beta$ amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013, 25, 1667-1677.	0.6	24
101	Cognitive Decline in Adults with Amnesic Mild Cognitive Impairment and High Amyloid- β : Prodromal Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1167-1176.	1.2	34
102	Health professionals' and students' perceptions of elder abuse. <i>Australasian Journal on Ageing</i> , 2013, 32, 48-51.	0.4	10
103	Cognitive consequences of high $A\beta$ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease.. <i>Neuropsychology</i> , 2013, 27, 322-332.	1.0	33
104	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 33, 675-679.	1.2	62
105	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 853-863.	0.8	13
106	Relationship between Memory Performance and β -Amyloid Deposition at Different Stages of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2012, 10, 141-144.	0.8	43
107	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012, 135, 2126-2139.	3.7	222
108	A surface based approach for cortical thickness comparison between PiB+ and PiB- healthy control subjects. <i>Proceedings of SPIE</i> , 2012, , .	0.8	2

#	ARTICLE	IF	CITATIONS
109	Lifestyle and late life cognitive health: sufficient evidence to act now?. <i>International Psychogeriatrics</i> , 2012, 24, 683-688.	0.6	2
110	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. <i>International Psychogeriatrics</i> , 2012, 24, 197-204.	0.6	39
111	Stronger effect of amyloid load than <i>APOE</i> genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012, 79, 1645-1652.	1.5	96
112	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1318.	4.9	348
113	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 345-358.	0.8	111
114	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. <i>BMC Psychiatry</i> , 2012, 12, 167.	1.1	40
115	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2012, 205, 96-109.	1.3	17
116	Memory improvements in elderly women following 16 weeks treatment with a combined multivitamin, mineral and herbal supplement. <i>Psychopharmacology</i> , 2012, 220, 351-365.	1.5	59
117	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 909-922.	1.2	83
118	Independent contribution of temporal β -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011, 134, 798-807.	3.7	132
119	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a PiB-PET longitudinal study. , 2011, 7, S6-S6.		0
120	Advances in structural and molecular neuroimaging in Alzheimer's disease. <i>Medical Journal of Australia</i> , 2011, 194, S20-3.	0.8	5
121	A web-based normative data tool for assessing cognitive performance in healthy older Australians. <i>Medical Journal of Australia</i> , 2011, 194, S12-4.	0.8	3
122	Examining the nature of impairment in visual paired associate learning in amnesic mild cognitive impairment. <i>Neuropsychology</i> , 2011, 25, 752-762.	1.0	25
123	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. <i>Neuropsychologia</i> , 2011, 49, 2384-2390.	0.7	139
124	Longitudinal assessment of β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	2.8	730
125	Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 173-178.	0.7	115
126	Association of Plasma A β Peptides with Blood Pressure in the Elderly. <i>PLoS ONE</i> , 2011, 6, e18536.	1.1	19

#	ARTICLE	IF	CITATIONS
127	Relationship between atrophy and β -amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 317-324.	2.8	322
128	Plasma Amyloid- β^2 as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1233-1242.	1.2	122
129	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010, 133, 3349-3358.	3.7	130
130	Supervised method to build an atlas database for multi-atlas segmentation-propagation. <i>Proceedings of SPIE</i> , 2010, , .	0.8	0
131	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010, 31, 1275-1283.	1.5	885
132	Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010, 6, 291-296.	0.4	53
133	IC-01-03: Larger temporal volume in asymptomatic elderly with high versus low beta-amyloid deposition. , 2010, 6, S2-S3.		1
134	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 672-687.	0.6	661
135	The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls. <i>Human Psychopharmacology</i> , 2008, 23, 151-159.	0.7	15
136	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. <i>NeuroImage</i> , 2008, 43, 430-439.	2.1	81
137	Tyrosine depletion alters cortical and limbic blood flow but does not modulate spatial working memory performance or task-related blood flow in humans. <i>Human Brain Mapping</i> , 2007, 28, 1136-1149.	1.9	12
138	Exploring the temporal dynamics of the spatial working memory n-back task using steady state visual evoked potentials (SSVEP). <i>NeuroImage</i> , 2006, 31, 1741-1751.	2.1	51
139	Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 175.	1.0	126
140	Muscarinic and nicotinic receptor modulation of object and spatial -back working memory in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 575-584.	1.3	108
141	Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans. <i>Psychopharmacology</i> , 2005, 181, 771-780.	1.5	15
142	The pharmacology of human working memory. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 299-313.	1.0	81